» Articles » PMID: 31203387

Uses for Humanised Mouse Models in Precision Medicine for Neurodegenerative Disease

Overview
Journal Mamm Genome
Specialty Genetics
Date 2019 Jun 17
PMID 31203387
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative disease encompasses a wide range of disorders afflicting the central and peripheral nervous systems and is a major unmet biomedical need of our time. There are very limited treatments, and no cures, for most of these diseases, including Alzheimer's Disease, Parkinson's Disease, Huntington Disease, and Motor Neuron Diseases. Mouse and other animal models provide hope by analysing them to understand pathogenic mechanisms, to identify drug targets, and to develop gene therapies and stem cell therapies. However, despite many decades of research, virtually no new treatments have reached the clinic. Increasingly, it is apparent that human heterogeneity within clinically defined neurodegenerative disorders, and between patients with the same genetic mutations, significantly impacts disease presentation and, potentially, therapeutic efficacy. Therefore, stratifying patients according to genetics, lifestyle, disease presentation, ethnicity, and other parameters may hold the key to bringing effective therapies from the bench to the clinic. Here, we discuss genetic and cellular humanised mouse models, and how they help in defining the genetic and environmental parameters associated with neurodegenerative disease, and so help in developing effective precision medicine strategies for future healthcare.

Citing Articles

Long-Term Engraftment of Cryopreserved Human Neurons for In Vivo Disease Modeling in Neurodegenerative Disease.

Marmion D, Deng P, Hiller B, Lewis R, Harms L, Cameron D Biology (Basel). 2025; 14(2).

PMID: 40001985 PMC: 11852092. DOI: 10.3390/biology14020217.


NMDA Receptors in Neurodevelopmental Disorders: Pathophysiology and Disease Models.

Tumdam R, Hussein Y, Garin-Shkolnik T, Stern S Int J Mol Sci. 2024; 25(22).

PMID: 39596430 PMC: 11594297. DOI: 10.3390/ijms252212366.


Preclinical research (on rare diseases): we need to talk about health equity.

Greenfield A Mamm Genome. 2024; .

PMID: 39461919 DOI: 10.1007/s00335-024-10080-1.


Emerging Human Pluripotent Stem Cell-Based Human-Animal Brain Chimeras for Advancing Disease Modeling and Cell Therapy for Neurological Disorders.

Ji Y, McLean J, Xu R Neurosci Bull. 2024; 40(9):1315-1332.

PMID: 38466557 PMC: 11365908. DOI: 10.1007/s12264-024-01189-z.


Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease.

Qin H, Zhou L, Haque F, Martin-Jimenez C, Trang A, Benveniste E J Neurochem. 2023; 168(10):3536-3557.

PMID: 37932959 PMC: 11839148. DOI: 10.1111/jnc.16002.


References
1.
Sud R, Geller E, Schellenberg G . Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies. Mol Ther Nucleic Acids. 2014; 3:e180. PMC: 4121519. DOI: 10.1038/mtna.2014.30. View

2.
Morselli E, Maiuri M, Markaki M, Megalou E, Pasparaki A, Palikaras K . Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis. 2011; 1:e10. PMC: 3032517. DOI: 10.1038/cddis.2009.8. View

3.
Pang T, Stam N, Nithianantharajah J, Howard M, Hannan A . Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience. 2006; 141(2):569-584. DOI: 10.1016/j.neuroscience.2006.04.013. View

4.
Sanchez-Rivera F, Papagiannakopoulos T, Romero R, Tammela T, Bauer M, Bhutkar A . Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014; 516(7531):428-31. PMC: 4292871. DOI: 10.1038/nature13906. View

5.
Wiseman F, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz V . A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015; 16(9):564-74. PMC: 4678594. DOI: 10.1038/nrn3983. View